PI
PIG.F Perrigo Company plc
- Market cap
- EUR 2.01B
- P/E
- -
- P/B
- 0.94x
- ROE
- -19.2%
- Dividend yield
- 6.99%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PIG.F undervalued?
Graham numberThe Graham number of Perrigo Company plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Perrigo Company plc fundamental analysis
No fundamental analysis for Perrigo Company plc yet.
Perrigo Company plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-dia…
Full company profilePerrigo Company plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Perrigo Company plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 5.28B | 4.95B | 4.73B | 4.84B | 5.06B | 4.14B | 4.45B | 4.66B | 4.37B | 4.25B | 3.97B |
| Gross Profit | 2.05B | 1.98B | 1.83B | 1.77B | 1.82B | 1.42B | 1.46B | 1.68B | 1.54B | 1.49B | 1.28B |
| Operating Income | 662M | 707M | 482M | 416M | 466M | 600M | 121M | 284M | 312M | 313M | 133M |
| EBITDA | - | 1.15B | 906M | 812M | 360M | 696M | 460M | 525M | 433M | -798M | 85.6M |
| Net Income | -4.01B | 120M | 131M | 146M | -163M | -68.9M | -141M | -12.7M | -172M | -1.43B | -469M |
| EPS | - | 0.85 | 0.96 | 1.07 | -1.22 | -0.51 | -1.04 | -0.09 | -1.26 | -10 | -3.38 |
| Balance Sheet | |||||||||||
| Total Assets | 13.9B | 11.6B | 11.0B | 11.3B | 11.5B | 10.4B | 11.0B | 10.8B | 9.65B | 8.54B | 7.48B |
| Total Liabilities | 7.91B | 5.46B | 5.32B | 5.50B | 5.83B | 5.27B | 6.18B | 6.04B | 5.33B | 5.60B | 5.04B |
| Shareholders' Equity | 5.96B | 6.17B | 5.67B | 5.80B | 5.66B | 5.15B | 4.84B | 4.77B | 4.32B | 2.94B | 2.44B |
| Cash & Short-term Investments | 622M | 679M | 551M | 354M | 642M | 1.86B | 601M | 751M | 559M | 532M | 437M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 655M | 699M | 593M | 388M | 636M | 156M | 307M | 406M | 363M | 239M | 86.9M |
| Capital Expenditure | 106M | 88.6M | 138M | 287M | 206M | 223M | 96.4M | 102M | 118M | 93.4M | 60.8M |
| Free Cash Flow | - | 610M | 490M | 250M | 466M | 4.20M | 211M | 304M | 245M | 145M | 26.1M |
| Ratios | |||||||||||
| ROE | -67.4% | 1.9% | 2.3% | 2.5% | -2.9% | -1.3% | -2.9% | -0.3% | -4.0% | -48.6% | -19.2% |
| ROA | -28.9% | 1.0% | 1.2% | 1.3% | -1.4% | -0.7% | -1.3% | -0.1% | -1.8% | -16.7% | -6.3% |
| Net Profit Margin | -76.0% | 2.4% | 2.8% | 3.0% | -3.2% | -1.7% | -3.2% | -0.3% | -3.9% | -33.5% | -11.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Perrigo Company plc dividends
- Dividend yield
- 6.99%
- Forward dividend
- 1.04 EUR
- Payout ratio
- -
- Ex-dividend date
- Nov 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 159M | 1.16 | - |
| 2024 | USD 153M | 1.12 | - |
| 2023 | USD 150M | 1.10 | - |
| 2022 | USD 142M | 1.06 | - |
| 2021 | USD 130M | 0.97 | - |
| 2020 | USD 124M | 0.93 | - |
| 2019 | USD 112M | 0.83 | 76.9% |
| 2018 | USD 105M | 0.77 | 80.1% |
| 2017 | USD 91.1M | 0.65 | 76.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Perrigo Company plc
- Insiders 0.39%
- Institutions 99.61%
- Public & others 0.00%
- Shares outstanding 139M
- Free float 138M
Perrigo Company plc company profile
- Company name
- Perrigo Company plc
- Ticker
- PIG.F
- ISIN
- IE00BGH1M568
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 8,100
- Fiscal year end
- December
- Address
- The Sharp Building, Dublin, Ireland, D02 TY74
- Phone
- 353 1 709 4000
- Website
- perrigo.com
About Perrigo Company plc
Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments. It offers upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and oral electrolyte beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. The company also offers healthy lifestyle products, such as smoking cessation and well-being products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; and other miscellaneous self-care products. It sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, and Compeed brands. The company also offers contract manufacturing services. It sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Perrigo Company plc management
10- Mr. Albert Ange ManzoneInterim President, Interim CEO & Director · born 1963
- Mr. Eduardo Guarita BezerraExecutive VP & CFO · born 1976
- Ms. Abbie LennoxEVP & Chief Scientific Officer · born 1981
- Mr. Charles AtkinsonExecutive VP, General Counsel & Secretary · born 1977
- Mr. Roberto KhouryExecutive VP & Chief Commercial Officer · born 1981
- Mr. Eric S. JacobsonVice President of Global Investor Relations
- Mr. Robert WillisChief Human Resources Officer & Executive VP · born 1969
- Dr. David BallEVP and Chief Brand & Digital Officer · born 1980
- Mr. Matthew WintermanExecutive Vice President of Product Supply, Operations Strategy & Transformation Officer · born 1971
- Ms. Sonia HolliesSenior VP & Treasurer